Last updated: February 13, 2026
Drug Overview and Market Position
NDC 69367-0387 corresponds to Rebinyn (coagulation factor IX, recombinant) marketed by Novo Nordisk. It is a recombinant factor IX concentrate used for the treatment and prophylaxis of bleeding episodes in patients with hemophilia B.
Market Size and Demand Drivers
- Prevalence of Hemophilia B: Approximately 1 in 30,000 male births globally. Estimated total patient population exceeds 40,000 individuals.
- Current Treatment Paradameworks: Regular prophylactic infusions; increasing shift toward personalized, recombinant treatments.
- Competitor Landscape: Other Factor IX products include Pfizer’s Ixinity, STILAREX from Sobi, and non-factor therapies like emicizumab (Hemlibra).
Market Trends
- Increasing adoption of recombinant products over plasma-derived therapies due to lower risk of viral transmission.
- Shift toward extended half-life products: recombinant FIX variants with longer dosing intervals are gaining market share.
- Growth driven by expanding global access, especially in emerging markets, though price sensitivity remains high.
Pricing Overview
- United States (US): Wholesale Acquisition Cost (WAC) for Rebinyn has been approximately $1.85 per unit, translating into annual treatment costs around $350,000–$400,000 per patient.
- Europe: List prices vary from €120,000 to €150,000 annually, depending on healthcare system negotiations.
- Asia-Pacific and other regions: Prices often reduced through negotiated discounts and tiered pricing strategies.
Price Trends and Projections (2023–2028)
| Year |
US Average Price per Unit |
Approximate Annual Cost per Patient |
Major Influences |
| 2023 |
$1.85 |
$350,000–$400,000 |
Market stabilizes, steady demand |
| 2024 |
$1.80–$1.90 |
$340,000–$410,000 |
Competitive pressures, potential generic/biosimilar entry |
| 2025 |
$1.75–$1.85 |
$330,000–$390,000 |
Biosimilar development activity accelerates |
| 2026 |
$1.70–$1.80 |
$320,000–$370,000 |
Increased biosimilar market penetration |
| 2027 |
$1.65–$1.75 |
$310,000–$355,000 |
Market consolidation, shifting pricing strategies |
| 2028 |
$1.60–$1.70 |
$300,000–$340,000 |
Cost containment policies impact pricing |
Key Market Drivers Influencing Price Trends
- Biosimilar Competition: Entry of biosimilars could reduce prices by 20–30%. Regulatory pathways are established in the US and EU, with multiple candidates in late-stage development.
- Global Access Programs: Pricing often adjusted in emerging markets; potential for significant discounts.
- Advances in Formulation: Longer-acting products may justify higher initial prices but could lead to overall reduced treatment costs per year.
- Healthcare Policy: Payer efficiencies and legislation aimed at cost reduction influence retail and negotiated prices.
Regulatory and Competitive Considerations
- Biosimilar Approvals: Pfizer, Sobi, and others are developing biosimilar Factor IX products, likely to reach markets between 2024 and 2027.
- Market Share Projections: Rebinyn’s market share expected to decrease from approximately 70% (2023) to less than 40% by 2028, with biosimilars gaining traction.
- Pricing Strategies: Novo Nordisk may implement tiered pricing, discounts, and patient assistance programs to retain market share.
Conclusion
Rebinyn remains a leading recombinant Factor IX therapy, with sustained demand driven by hemophilia B’s chronic nature. Prices are expected to decline gradually due to biosimilar competition, though novel formulations extending half-life will support higher price points initially. Payer pressure and global market expansion constitute key strategic environments influencing future pricing.
Key Takeaways
- Rebinyn’s current US price approximates $1.85 per unit with annual treatment costs around $350,000–$400,000.
- Market prices are projected to decline approximately 3–4% annually over the next five years due to biosimilar competition.
- Global pricing varies significantly, with emerging markets offering considerable discounts.
- Longer-acting products and biosimilars are primary drivers of future price dynamics.
- Regulatory approval of biosimilars from Pfizer, Sobi, and others will likely accelerate price reductions and market share shifts.
FAQs
1. What factors influence the price of Rebinyn?
Market demand, biosimilar competition, formulation innovations, healthcare policies, and negotiation with payers primarily impact pricing.
2. How will biosimilar entries affect Rebinyn’s market share?
Biosimilar products are expected to capture 50–60% of the market by 2028, reducing Rebinyn’s market share from approximately 70% in 2023.
3. Are prices of hemophilia B treatments likely to decrease significantly?
Yes, significant decreases are anticipated, especially with biosimilar competition, though new extended half-life products may support price stability temporarily.
4. How does global pricing vary?
Developed markets like the US and Europe maintain higher prices, while emerging regions often see discounts of 30–50%.
5. What opportunities exist for market growth?
Expanding access in emerging markets and developing longer-acting formulations present growth avenues. Investment in biosimilars also provides opportunities.
References
[1] IQVIA. Hemophilia Market Report 2022.
[2] EvaluatePharma. Hemophilia Market Outlook 2023–2028.
[3] FDA. Biosimilar Approval Pathways.
[4] Sobi, Pfizer, and Novo Nordisk investor presentations.
[5] European Medicines Agency. Hemophilia Treatment Approvals.
